Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CytoDyn, a biotechnology company, has signed a Research Funding and Option Agreement with The Scripps Research Institute to explore the potential of CytoFeline in the treatment of feline immunodeficiency virus (FIV).
Subscribe to our email newsletter
The company recently filed its first provisional patent application for use of anti-adhesion molecule therapies to treat FIV infections, and has identified three candidate antibodies that are likely to have potential for activity in the feline system.
FIV has been reported to cause an AIDS-like syndrome in the domestic cat and is a distant relative of HIV, the cause of AIDS in humans, the company said.
The company said that currently there is no satisfactory therapeutic treatment for FIV on the market.